FDA clears GE's Advanced Lung Analysis package
GE Healthcare has won FDA clearance for its next-generation Advanced Lung Analysis technology to help radiologists evaluate and assess nodules and other lesions in the lung.
The FDA clearance included a new feature within AdvantageALA called digital contrast agent (DCA) that automatically highlights suspicious anatomical regions such as lung nodules to assist and complement the physician during the reading process.
The FDA clearance included a new feature within AdvantageALA called digital contrast agent (DCA) that automatically highlights suspicious anatomical regions such as lung nodules to assist and complement the physician during the reading process.